PL2590998T3 - SPOSÓB WYTWARZANIA REKOMBINOWANEGO vWF O DUŻEJ MASIE CZĄSTECZKOWEJ W HODOWLI KOMÓRKOWEJ - Google Patents

SPOSÓB WYTWARZANIA REKOMBINOWANEGO vWF O DUŻEJ MASIE CZĄSTECZKOWEJ W HODOWLI KOMÓRKOWEJ

Info

Publication number
PL2590998T3
PL2590998T3 PL11736502T PL11736502T PL2590998T3 PL 2590998 T3 PL2590998 T3 PL 2590998T3 PL 11736502 T PL11736502 T PL 11736502T PL 11736502 T PL11736502 T PL 11736502T PL 2590998 T3 PL2590998 T3 PL 2590998T3
Authority
PL
Poland
Prior art keywords
molecular weight
cell culture
high molecular
producing recombinant
weight vwf
Prior art date
Application number
PL11736502T
Other languages
English (en)
Inventor
Leopold Grillberger
Manfred Reiter
Wolfgang Mundt
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2590998(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of PL2590998T3 publication Critical patent/PL2590998T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
PL11736502T 2010-07-08 2011-07-08 SPOSÓB WYTWARZANIA REKOMBINOWANEGO vWF O DUŻEJ MASIE CZĄSTECZKOWEJ W HODOWLI KOMÓRKOWEJ PL2590998T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36263510P 2010-07-08 2010-07-08
EP11736502.3A EP2590998B1 (en) 2010-07-08 2011-07-08 METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE
PCT/US2011/043455 WO2012006591A1 (en) 2010-07-08 2011-07-08 METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE

Publications (1)

Publication Number Publication Date
PL2590998T3 true PL2590998T3 (pl) 2018-05-30

Family

ID=44514323

Family Applications (4)

Application Number Title Priority Date Filing Date
PL11738351T PL2591094T3 (pl) 2010-07-08 2011-07-08 Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej
PL11736502T PL2590998T3 (pl) 2010-07-08 2011-07-08 SPOSÓB WYTWARZANIA REKOMBINOWANEGO vWF O DUŻEJ MASIE CZĄSTECZKOWEJ W HODOWLI KOMÓRKOWEJ
PL16153131.4T PL3064508T5 (pl) 2010-07-08 2011-07-08 Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
PL18175765T PL3392271T3 (pl) 2010-07-08 2011-07-08 Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11738351T PL2591094T3 (pl) 2010-07-08 2011-07-08 Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL16153131.4T PL3064508T5 (pl) 2010-07-08 2011-07-08 Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
PL18175765T PL3392271T3 (pl) 2010-07-08 2011-07-08 Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej

Country Status (25)

Country Link
US (8) US9458222B2 (pl)
EP (6) EP2591094B1 (pl)
JP (3) JP6138683B2 (pl)
KR (4) KR101894604B1 (pl)
CN (4) CN107286235A (pl)
AU (6) AU2011274470B2 (pl)
BR (2) BR112013000512A2 (pl)
CA (2) CA2804275A1 (pl)
CO (2) CO6690745A2 (pl)
DK (3) DK2590998T3 (pl)
EA (5) EA029503B1 (pl)
ES (4) ES2761692T5 (pl)
FI (1) FI3064508T4 (pl)
HR (3) HRP20192089T4 (pl)
HU (3) HUE038193T2 (pl)
IL (5) IL286298B (pl)
MX (3) MX2013000166A (pl)
NZ (2) NZ605404A (pl)
PL (4) PL2591094T3 (pl)
PT (3) PT2591094T (pl)
SG (3) SG10201809632XA (pl)
SI (3) SI3064508T2 (pl)
TR (1) TR201815211T4 (pl)
TW (4) TWI670073B (pl)
WO (2) WO2012006594A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2745805C (en) * 2008-12-05 2021-01-19 Baxter International Inc. Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
BR112013000512A2 (pt) 2010-07-08 2016-05-17 Baxter Healthcare Sa método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)'
ES2682249T3 (es) 2011-06-10 2018-09-19 Baxalta GmbH Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
US9030963B2 (en) * 2012-12-03 2015-05-12 Honeywell International Inc. Analyzing a network topology
UY35343A (es) * 2013-02-26 2014-09-30 Bayer Healthcare Llc Formulaciones y procedimientos para la producción de proteína recombinante aumentada
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
US10544231B2 (en) 2014-04-16 2020-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
EP3158055B1 (en) * 2014-06-13 2019-09-11 CSL Limited Improved production of recombinant von willebrand factor in a bioreactor
MA41685A (fr) * 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
KR102638596B1 (ko) * 2015-02-05 2024-02-21 알.피.쉐러 테크놀러지즈 엘엘씨 활성화된 포르밀글리신-생성 효소 및 그것의 생산 및 사용 방법
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
AU2017307582C1 (en) 2016-08-04 2021-05-06 Takeda Pharmaceutical Company Limited Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
CN106957815B (zh) * 2017-03-16 2021-05-07 杨涛 一种用于人类多潜能干细胞的无血清培养基的配方
WO2019010497A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION
EP3648787A1 (en) 2017-07-07 2020-05-13 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
BR112020019057A2 (pt) 2018-03-21 2020-12-29 Baxalta Incorporated Método para obter uma composição, e, composição farmacêutica.
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10961500B1 (en) 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
AU2021216945A1 (en) 2020-02-04 2022-09-01 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von Willebrand Disease by administration of recombinant VWF
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
NL8500961A (nl) 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
AU591671B2 (en) 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP1213030B1 (en) 1994-11-10 2009-04-22 Baxter Healthcare SA Method for producing biologicals in protein-free culture
CA2211630A1 (en) 1995-02-23 1996-08-29 Quest International B.V. Peptides for tissue and cell culture media
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2000517188A (ja) 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
ATE399855T1 (de) 1996-10-10 2008-07-15 Invitrogen Corp Tierzellkulturmedium mit pflanzlichen nährstoffen
US6156570A (en) * 1997-03-20 2000-12-05 Regents Of The University Of Minnesota Process for the continuous culture of cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP2001120262A (ja) 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1596302A (zh) * 2001-11-28 2005-03-16 桑多斯有限公司 细胞培养方法
JP2005532033A (ja) 2002-01-17 2005-10-27 ロンザ・バイオロジクス・ピーエルシー タンパク質を産生する能力を有し且つ無グルタミン培地中で成長する能力を有するグルタミン栄養要求性ヒト細胞
US20050084828A1 (en) 2003-10-21 2005-04-21 The University Of North Carolina At Chapel Hill Apparatus and method for braille instruction
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US8273553B2 (en) * 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
EP1807504B1 (en) * 2004-11-02 2011-02-23 Ares Trading S.A. Serum-free cell culture medium for mammalian cells
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US20070212770A1 (en) 2006-01-04 2007-09-13 Baxter International Inc. Oligopeptide-free cell culture media
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN101490239A (zh) * 2006-07-14 2009-07-22 帝斯曼知识产权资产管理有限公司 改进的细胞培养方法
TW201516149A (zh) * 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
US7960869B2 (en) 2006-09-22 2011-06-14 Siemens Industry, Inc. Internal intelligence for remote operated relay
JP5702066B2 (ja) * 2006-12-27 2015-04-15 ネクター セラピューティクス 解離可能な連結を有するフォンウィルブランド因子および第ｖｉｉｉ因子のポリマー共役体
EP2115126B1 (en) * 2007-03-02 2015-04-08 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
DE102007046611A1 (de) * 2007-09-28 2009-04-02 Osram Opto Semiconductors Gmbh Lichtquelle mit Konversionselement und Lichtwellenleiter, Verfahren zur Herstellung der Lichtquelle und deren Verwendung
SG10201503304RA (en) * 2007-12-27 2015-06-29 Baxter Int Cell culture processes
PT2240578T (pt) 2007-12-31 2019-06-19 Baxalta GmbH Furina recombinante substancialmente isenta de proteínas animais e métodos para a sua produção
JP4458167B2 (ja) * 2008-01-11 2010-04-28 住友金属工業株式会社 熱間塑性加工用潤滑剤を用いる継目無管製造における外面潤滑方法
WO2009116044A2 (en) 2008-03-19 2009-09-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compounds for treating bacterial infections
DK2310523T3 (en) * 2008-04-17 2015-07-20 Wyeth Llc Methods for increasing the production of bone morphogenetic proteins
US8486699B2 (en) 2008-05-23 2013-07-16 The United States Of America As Represented By The Secretary Of Agriculture Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
KR101574056B1 (ko) * 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
BR112013000512A2 (pt) 2010-07-08 2016-05-17 Baxter Healthcare Sa método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)'
TWI408228B (zh) 2010-10-29 2013-09-11 Univ Nat Chunghsing 用於生產一標的蛋白質的核酸建構物、重組型載體以及方法

Also Published As

Publication number Publication date
US20190085052A1 (en) 2019-03-21
JP2013533748A (ja) 2013-08-29
EA035066B1 (ru) 2020-04-23
JP2017217004A (ja) 2017-12-14
AU2022200035A1 (en) 2022-01-20
JP6138683B2 (ja) 2017-05-31
ES2761692T3 (es) 2020-05-20
EP2591094B1 (en) 2018-09-05
KR20130091328A (ko) 2013-08-16
SG186935A1 (en) 2013-02-28
KR101894604B1 (ko) 2018-09-03
EA201792340A3 (ru) 2018-07-31
TR201815211T4 (tr) 2018-11-21
MX339632B (es) 2016-06-02
EP3392271B1 (en) 2021-05-05
EA201792340A2 (ru) 2018-02-28
US9458222B2 (en) 2016-10-04
HRP20192089T4 (hr) 2023-04-28
DK3064508T4 (da) 2023-04-11
AU2011274467A1 (en) 2013-01-24
KR20180099922A (ko) 2018-09-05
IL286298A (en) 2021-10-31
IL255327B (en) 2020-04-30
SI2590998T1 (en) 2018-06-29
WO2012006594A1 (en) 2012-01-12
PL3064508T3 (pl) 2020-02-28
MX353409B (es) 2018-01-11
HRP20180136T1 (hr) 2018-04-06
IL273304B (en) 2021-09-30
EP2590998A1 (en) 2013-05-15
SI3064508T2 (sl) 2023-05-31
AU2018200206A1 (en) 2018-04-05
AU2020203565B2 (en) 2021-09-30
MX2013000166A (es) 2013-06-05
EA202090067A2 (ru) 2020-04-30
EP3064508B2 (en) 2023-03-15
CN103097409A (zh) 2013-05-08
US11780904B2 (en) 2023-10-10
FI3064508T4 (fi) 2023-04-25
CN108060154A (zh) 2018-05-22
SG186936A1 (en) 2013-02-28
PL3064508T5 (pl) 2024-04-08
KR102007773B1 (ko) 2019-08-06
EP3626736A1 (en) 2020-03-25
EA201390080A1 (ru) 2013-06-28
US20150056657A1 (en) 2015-02-26
US20180044405A1 (en) 2018-02-15
KR20130091329A (ko) 2013-08-16
US9409971B2 (en) 2016-08-09
US10822394B2 (en) 2020-11-03
HRP20192089T1 (hr) 2020-03-20
AU2015207811A1 (en) 2015-08-20
CO6690745A2 (es) 2013-06-17
EP2591094A1 (en) 2013-05-15
PL3392271T3 (pl) 2021-11-15
EA202090220A3 (ru) 2020-08-31
HUE046443T2 (hu) 2020-03-30
MX2013000165A (es) 2013-06-05
PT2590998T (pt) 2018-02-13
IL223930A (en) 2017-01-31
NZ605404A (en) 2014-08-29
CA2804275A1 (en) 2012-01-12
EP3392271A1 (en) 2018-10-24
CA2805557A1 (en) 2012-01-12
IL286298B (en) 2022-08-01
IL255327A0 (en) 2017-12-31
JP2013538046A (ja) 2013-10-10
DK3064508T3 (da) 2019-11-25
EA201390082A1 (ru) 2013-06-28
WO2012006591A1 (en) 2012-01-12
AU2011274470A1 (en) 2013-01-24
AU2015207811B2 (en) 2017-10-19
EA035147B1 (ru) 2020-05-06
AU2011274470B2 (en) 2015-08-13
DK2591094T3 (en) 2018-11-26
PL2591094T3 (pl) 2019-02-28
ES2761692T5 (es) 2023-07-05
JP6284919B2 (ja) 2018-02-28
EP3064508B1 (en) 2019-08-28
TW201900207A (zh) 2019-01-01
EA202090220A2 (ru) 2020-05-31
ES2875772T3 (es) 2021-11-11
TWI670073B (zh) 2019-09-01
US20120035110A1 (en) 2012-02-09
PT3064508T (pt) 2019-12-05
EA202090067A3 (ru) 2020-07-31
AU2018200206B2 (en) 2020-05-28
US9834591B2 (en) 2017-12-05
BR112013000512A2 (pt) 2016-05-17
HRP20181657T1 (hr) 2019-03-08
AU2011274467B2 (en) 2015-01-15
SI3064508T1 (sl) 2019-12-31
SI2591094T1 (sl) 2018-12-31
EP3909977A1 (en) 2021-11-17
DK2590998T3 (en) 2018-02-12
CN103097522A (zh) 2013-05-08
EP3064508A1 (en) 2016-09-07
TWI609890B (zh) 2018-01-01
AU2020203565A1 (en) 2020-06-18
TWI617575B (zh) 2018-03-11
US10100099B2 (en) 2018-10-16
KR101924120B1 (ko) 2018-11-30
NZ605403A (en) 2014-10-31
CO6680636A2 (es) 2013-05-31
ES2664392T3 (es) 2018-04-19
SG10201809632XA (en) 2018-12-28
JP5953502B2 (ja) 2016-07-20
EP3392271B8 (en) 2021-06-16
ES2694518T3 (es) 2018-12-21
KR102027991B1 (ko) 2019-10-02
TW201206953A (en) 2012-02-16
EA029503B1 (ru) 2018-04-30
CN107286235A (zh) 2017-10-24
US20170008948A1 (en) 2017-01-12
TWI646972B (zh) 2019-01-11
KR20180130587A (ko) 2018-12-07
BR112013000515A2 (pt) 2016-05-17
EP2590998B1 (en) 2017-11-15
JP2016025873A (ja) 2016-02-12
IL223929A (en) 2017-11-30
BR112013000515B1 (pt) 2021-11-03
HUE11738351T2 (hu) 2019-03-28
US20150018525A1 (en) 2015-01-15
HUE038193T2 (hu) 2018-09-28
PT2591094T (pt) 2018-11-20
TW201204744A (en) 2012-02-01
US8852888B2 (en) 2014-10-07
IL273304A (en) 2020-04-30
US20210115110A1 (en) 2021-04-22
US20120034674A1 (en) 2012-02-09
TW201637665A (zh) 2016-11-01

Similar Documents

Publication Publication Date Title
IL286298A (en) A method to generate high molecular weight substituted vwf in cell culture
IL288509A (en) Mammalian cell culture
HRP20182165T1 (hr) Postupak proizvodnje polipeptida ili virusa od interesa u kontinuiranoj staničnoj kulturi
HRP20190484T1 (hr) Pripravci stanične kulture i postupci proizvodnje polipeptida
EP2530729A4 (en) SOLAR CELL AND METHOD OF MANUFACTURING THE SAME
GB2491209B (en) Solar cell and method for producing same
GB201113641D0 (en) Cell culture support and cell culture method
EP2699672A4 (en) METHOD FOR PRODUCING VIRUSES IN CULTURED CELLS
EP2787547A4 (en) POLYMERIC SOLAR CELL AND PROCESS FOR PREPARING THE SAME
IL225348A0 (en) A method for obtaining a cell population rich in desired cells
GB201020075D0 (en) Mammalian cell transformation method